Arterial hypertension. Angina (including post-infarction). Arrhythmia (including supraventricular tachycardia). Prevention of cardiac death and re-infarction after the acute phase of myocardial infarction. As part of complex therapy for thyrotoxicosis. Prevention of migraine attacks.
Egylok 50 mg Storage
active substance: metoprolol;
1 tablet contains metoprolol tartrate 25 mg or 50 mg or 100 mg;
Egylok 50 mg Excipients: magnesium stearate, povidone, colloidal anhydrous silica, sodium starch glycolate (type A), microcrystalline cellulose.
Egylok 50 mg Dosage form
Basic physical and chemical properties:
25 mg: white or almost white round biconvex tablets with a cross-shaped score line and a double bevel (“double sheaf”) on one side and engraved with the stylized letter “E” and the number 435 on the other side, odorless or almost odorless;
50 mg: white or almost white round biconvex tablets with a dash on one side and engraved with the stylized letter “E” and the number 434 on the other side, without or almost odorless;
100 mg: white or almost white round biconvex tablets, bevelled, dashed on one side and engraved with the stylized letter “E” and the number 432 on the other side, odorless or almost odorless.
The tablets can be divided into equal parts.
Selective β-adrenoceptor blockers.
ATX code C07A B02.
Metoprolol is a cardioselective β1-adrenoceptor blocker. Does not have a membrane-stabilizing effect and has no internal sympathomimetic activity.
It suppresses the cardiac effects of increased sympathetic activity, significantly reduces heart rate, heart rate, cardiac output and blood pressure.
In hypertension, metoprolol lowers blood pressure in patients both in the standing position and in the supine position. Prolonged antihypertensive effect of the drug
associated with a gradual decrease in total peripheral vascular resistance.
In patients with hypertension, long-term use of the drug leads to a statistically significant decrease in left ventricular mass and improved diastolic function of the left ventricle.
In men with mild to moderate hypertension, metoprolol reduces cardiovascular mortality (primarily the incidence of sudden fatalities, fatal myocardial infarction, and stroke).
Angina pectoris (including postinfarction).
Arrhythmia (including supraventricular tachycardia).
Prevention of cardiac death and recurrent heart attack after the acute phase of myocardial infarction.
As a part of complex therapy at a thyrotoxicosis.
Prevention of migraine attacks.
Hypersensitivity to any component of the drug or to other β-blockers;
atrioventricular block (AV block) of II and III degrees, sinoatrial block;
sinus node weakness syndrome;
decompensated heart failure (pulmonary edema, hypoperfusion syndrome or hypotension); long-term or periodic isotropic therapy with β-receptor agonists;
severe bradycardia (heart rate (HR) ≤ 45 per 1 min);
severe peripheral circulatory disorders with pain or trophic changes;
arterial hypotension (systolic blood pressure <100 mm Hg);
long-term or periodic inotropic therapy with β-receptor agonists;
concomitant therapy with monoamine oxidase-A inhibitors;
severe bronchial asthma, severe chronic obstructive pulmonary disease;
Metoprolol is contraindicated in patients receiving intravenous calcium antagonists such as verapamil and diltiazem or other antiarrhythmic drugs (such as disopyramide).
Metoprolol should not be used in patients with suspected acute myocardial infarction with a heart rate less than 45 beats / min, P – Q interval> 0.24 c, or systolic blood pressure <100 mm Hg.
Note. In patients with decompensated heart failure who are well tolerated by other drugs, the use of metoprolol is possible with individual dose titration.